Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Sandy Antoun

Nurse Practitioner Royal Oak, MI Nurse Practitioner

NPI 1194084400 CMS profile 10809797

3601 W 13 Mile Rd, Royal Oak, MI 48073

Open in the dashboard

General payments

$5,190

150 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sandy Antoun of Royal Oak, MI is reported in the CMS Open Payments database as having received $5,190 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,398 117
2024 General $771 32
2023 General $21 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandy Antoun
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sandy Antoun were reported at $4,398. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sandy Antoun Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $21 $166 $54–$529 $160
2024 $771 $173 $55–$556 $164
2025 $4,398 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Merck Sharp & Dohme Corporation $1,957 12 payments
  2. AbbVie, Inc. $1,028 51 payments
  3. Janssen Biotech, Inc. $432 26 payments
  4. Madrigal Pharmaceuticals $415 6 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $295 15 payments
  6. Jazz Pharmaceuticals Inc. $247 2 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $219 16 payments
  8. Ardelyx, Inc. $162 9 payments
  9. Alexion Pharmaceuticals, Inc. $126 1 payment
  10. Lilly USA, LLC $122 1 payment
  11. Other $187 11 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,673 143 payments
  2. Travel and Lodging $1,517 7 payments
Products named General payments · program years 2023–2025
  1. RINVOQ $735 36 payments
  2. SKYRIZI Immunology $675 31 payments
  3. TREMFYA $432 26 payments
  4. REZDIFFRA $415 6 payments
  5. XIFAXAN $295 15 payments
  6. Epidiolex $247 2 payments
  7. ENTYVIO $219 16 payments
  8. SKYRIZI Immunology $192 9 payments
  9. IBSRELA $162 9 payments
  10. OMVOH $122 1 payment
  11. Other $357 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$11,368

Medicare's payments for the services billed

Medicare patients

147

Average age 76

Services billed

155

75 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 63%
Heart failure 61%
Chronic kidney disease 54%
Atrial fibrillation 51%
Diabetes 46%
Depression 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OMVOH
  • Lilly USA, LLC $122
$122 — —
RINVOQ
  • AbbVie, Inc. $99
$99 — —
SKYRIZI
  • AbbVie, Inc. $96
$96 — —
TREMFYA
  • Janssen Biotech, Inc. $62
$62 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record